Does Left Ventricular Augmentation with Algisyl in addition to SMT improve exercise capacity, symptoms, and clinical status in patients with advanced HF?
Left ventricular augmentation with Algisyl added to standard medical therapy provides sustained 1-year improvements in exercise capacity and symptoms in patients with advanced heart failure.
Algisyl in addition to SMT was more effective than SMT alone for providing sustained 1-year benefits in exercise capacity, symptoms, and clinical status for patients with advanced HF. These data support larger clinical evaluations of this novel therapy.
Mann et al. (Wed,) studied this question.